Proactive Research analyst Emma Ulker discusses what she describes as the ground-breaking approach Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) is taking in the field of monoclonal antibodies. She says their lead programme Foralumab is notable in that not only is it the only fully human anti-CD3 specific mAb in clinical development, with broad potential for a range of inflammatory and autoimmune diseases, but also due to the novel proprietary formulations being developed by the company for nasal and oral administration.
Click here to read Tiziana Life Sciences: Transformational potential